Will hemoperfusion be useful for cancer chemotherapeutic drug removal?
One of the major problems in clinical cancer chemotherapy is the inability to safely administer full therapeutic doses of specific drugs in the face of dysfunction of an organ system controlling that drug's metabolism and excretion. Should efficient drug removal from blood be possible following full therapeutic doses and after tumor exposure, then theoretically, even in the presence of organ dysfunction, anticancer drug toxicity may be reduced or avoided. Preliminary experiments in our laboratory have shown that adriamycin may be efficiently removed by activated charcoal from aqueous and protein solutions and blood in vivo, and that daunorubicin is removed in vitro to the same extent. However, although methotrexate is removed efficiently in vitro and extracted 50% in vivo by charcoal hemoperfusion, its overall pharmacokinetics do not appear to be altered in comparison with the alteration in pharmacokinetics of adriamycin achieved with charcoal hemoperfusion. Computer modeling has suggested that efficient adriamycin removal is achievable, and that clinical studies are warranted. For methotrexate removal, however, previous clinical studies and our own data suggest that charcoal hemoperfusion has little utility unless a highly specific sorbent for methotrexate removal can be developed.
D000327:Adsorption; D000818:Animals; D000970:Antineoplastic Agents / Q000506:poisoning*; D003630:Daunorubicin / Q000097:blood / Q000506:poisoning; D004285:Dogs; D004317:Doxorubicin / Q000097:blood / Q000506:poisoning; D006464:Hemoperfusion; D008727:Methotrexate / Q000097:blood / Q000506:poisoning; D008954:Models, Biological
D000970:Antineoplastic Agents; D004317:Doxorubicin; D008727:Methotrexate; D003630:Daunorubicin